Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Guidelines for prescribing azathioprine in dermatology.

Anstey AV, Wakelin S, Reynolds NJ; British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee..

Br J Dermatol. 2004 Dec;151(6):1123-32. Review.

PMID:
15606506
2.

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.

Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K.

J Clin Pharm Ther. 2007 Apr;32(2):187-95.

PMID:
17381669
3.

Azathioprine in dermatology: a survey of current practice in the U.K.

Tan BB, Lear JT, Gawkrodger DJ, English JS.

Br J Dermatol. 1997 Mar;136(3):351-5.

PMID:
9115914
4.

Immunosuppressive agents in dermatology. An update.

Dutz JP, Ho VC.

Dermatol Clin. 1998 Apr;16(2):235-51. Review.

PMID:
9589197
5.

Azathioprine: a guide for the management of dermatology patients.

Wise M, Callen JP.

Dermatol Ther. 2007 Jul-Aug;20(4):206-15. Review.

PMID:
17970886
6.

Immunosuppressive agents in dermatology.

Ho VC, Zloty DM.

Dermatol Clin. 1993 Jan;11(1):73-85. Review.

PMID:
8435920
7.

Azathioprine in dermatology: the past, the present, and the future.

Patel AA, Swerlick RA, McCall CO.

J Am Acad Dermatol. 2006 Sep;55(3):369-89. Review.

PMID:
16908341
9.

Azathioprine in dermatology.

Bardek I, Milavec-Puretić V, Lipozencić J.

Acta Dermatovenerol Croat. 2007;15(4):264-8. Review.

PMID:
18093457
10.

Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.

Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M.

Arch Dermatol. 2008 Sep;144(9):1143-7. doi: 10.1001/archderm.144.9.1143.

PMID:
18794458
11.

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.

Ther Drug Monit. 2007 Feb;29(1):1-5.

PMID:
17304143
12.

British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.

Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S.

Br J Dermatol. 2011 Oct;165(4):711-34. doi: 10.1111/j.1365-2133.2011.10575.x. No abstract available.

PMID:
21950502
13.

[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].

Gisbert JP, González-Lama Y, Maté J.

Gastroenterol Hepatol. 2006 Nov;29(9):568-83. Review. Spanish.

PMID:
17129552
14.

[2/3 The antimetabolites (azathioprine and mycophenolate)].

Rave M, Limat S, Woronoff-Lemsi MC.

Soins. 2007 Jul-Aug;(717):57-8. French. No abstract available.

PMID:
17877258
15.

[Immunosuppressive therapy. A survey concerning rationale, risks, indications and contraindications].

Videbaek A.

Ugeskr Laeger. 1973 Oct 29;135(44):2372-7. Review. Danish. No abstract available.

PMID:
4590081
16.

TPMT testing in rheumatology: any better than routine monitoring?

Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Ollier WE.

Rheumatology (Oxford). 2007 May;46(5):727-9. No abstract available.

17.

Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.

Czaja AJ, Carpenter HA.

Dig Dis Sci. 2006 May;51(5):968-75.

PMID:
16773433
18.

[Medicamental immunosuppression in dermatology (author's transl)].

Goerz G, Merk H.

Z Hautkr. 1981 Aug 1;56(15):975-90. German.

PMID:
7269720
19.

Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: optimal levels as adjunctive tools for azathioprine monitoring.

el-Azhary RA, Farmer SA, Drage LA, Rogers RS 3rd, McEvoy MT, Davis MD, Bridges AG, Gibson LE.

Arch Dermatol. 2009 Jun;145(6):644-52. doi: 10.1001/archdermatol.2009.81.

PMID:
19528417
20.
Items per page

Supplemental Content

Support Center